110 documents

Read All
14:15 , Mar 20, 2019 |  BC Extra  |  Company News

Alexion augmenting pipeline with Zealand, Affibody deals

Alexion took a pair of steps toward further rebuilding its pipeline Wednesday, gaining rights to targets in the complement pathway via a deal with Zealand and adding a clinical-stage molecule from Affibody for IgG-mediated autoimmune...
Read More
00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
Read More
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Lilly is Dicerna's second RNAi partner within a week

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) on Oct. 29 to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna...
Read More
10:02 , Oct 29, 2018 |  BC Extra  |  Company News

Lilly is Dicerna's second RNAi partner in a week

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna has made within...
Read More
17:13 , Oct 26, 2018 |  BC Week In Review  |  Company News

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...
Read More
23:07 , Oct 24, 2018 |  BC Extra  |  Company News

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...
Read More
13:05 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight...
Read More
22:44 , Sep 13, 2018 |  BC Week In Review  |  Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) raised $100 million on Sept. 6 via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and SunTrust Robinson Humphrey. The price...
Read More
19:06 , Sep 7, 2018 |  BC Extra  |  Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.79 (14%) to $14.81 on Friday after raising $100 million via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and...
Read More
16:15 , Apr 27, 2018 |  BC Week In Review  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said on April 20 it has resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In 2015, Alnylam filed a suit...
Read More